PT-141 (Bremelanotide) vs Tadalafil Peptide
A side-by-side research comparison of PT-141 (Bremelanotide) and Tadalafil Peptide across mechanism, dosing, half-life, benefits, side effects and research status.
Comparison table
| Attribute | PT-141 (Bremelanotide) | Tadalafil Peptide |
|---|---|---|
| Full name | Bremelanotide (PT-141 / Vyleesi) | Tadalafil-Peptide Conjugate (Experimental) |
| Category | Sexual Health | Sexual Health |
| Status | FDA Approved | Research compound |
| Mechanism | MC4R agonist in hypothalamus activating central sexual arousal pathways. Increases dopaminergic signaling independent of vascular mechanisms. | CPP moiety facilitates targeted PDE5 inhibitor delivery to penile smooth muscle. Local PDE5 inhibition increases cGMP for NO-mediated vasodilation with reduced systemic exposure. |
| Molecular weight | 1,025 Da | ~2,500 Da (conjugate) |
| Half-life | 2.7 hours | 8-12 hours |
| Bioavailability | High (SubQ) | Targeted (topical/local) |
| Typical dose | 1.75 mg | 1-5 mg equivalent |
| Frequency | As needed, ~45 min before activity | As needed |
| Route | Subcutaneous injection | Topical or local injection |
PT-141 (Bremelanotide) reported benefits
- Increased sexual desire
- Central arousal mechanism
- Works both sexes (research)
- Non-vascular
- Rapid onset
Tadalafil Peptide reported benefits
- Targeted PDE5 inhibition
- Reduced systemic side effects
- Potentially faster onset
- Lower dose requirement
Related comparisons
Research and educational reference only. Not medical advice.